business
Forte Biosciences Acquired by Dutch Pharma Firm for $2.2B
Summary by The Dallas Editorial Desk Kim Lyons , as published by Dallas Innovates
· July 28, 2026
· 1 min read
Photo: Dallas Innovates · view original
Dallas Innovates, Every Day: Here's what's new + next in North Texas. Dallas-based biopharmaceutical company Forte Biosciences Inc. has been acquired by Netherlands pharmaceutical company Argenx for $2.2 billion, the companies announced. Argenx CEO Karen Massey said in a statement that Forte’s ex...
Sources and story details Story provenance No corrections
Summary created by The Dallas Editorial Desk — automated, rule-governed Byline on source page Kim Lyons, as published by Dallas Innovates Original story Read at the source Source published Jul 28, 2026 Indexed here Aug 4, 2026 AI assistance Automated summary drawn from the source’s own published text Prepublication human review No — editorial rules, flagged-item review, and published samples
Every story comes with a passport. How we work · Corrections log
Key takeaway Argenx CEO Karen Massey said in a statement that Forte’s experimental drug FB102 will add to the company’s ambition of being the “leading immunology innovator of the future.
Get more The Dallas stories like this
Free weekly briefing covering business and other local news. Curated by our editorial team. No spam.
By subscribing you agree to our privacy policy . Unsubscribe anytime.
Frequently asked about this story
What is this story about? Dallas Innovates, Every Day: Here's what's new + next in North Texas. Dallas-based biopharmaceutical company Forte Biosciences Inc. has been acquired by Netherlands pharmaceutical company Argenx for $2.2 billion, the companies announced. Argenx CEO Karen Massey said in a statement that Forte’s ex...
When was this published? This article was first published on July 28, 2026 by Dallas Innovates and curated for The Dallas readers.
Who reported this story? This story was reported by Kim Lyons at Dallas Innovates. To learn more about how The Dallas selects and reviews stories, see our editorial standards .
Where can I find related coverage? See more business coverage from The Dallas, or browse our daily briefing and topic hubs .
← Back to all news
More business →
Today’s briefing
Subscribe to newsletter
